Table 3.

Clinical measures after randomization in participants assigned to receive dietary potassium restriction or standard care

Variables	Control	Potassium Restriction	P Value
Change in eGFR,a ml/min per 1.73 m2	−5.4±8.5	−5.2±7.9	0.91
Final eGFR, ml/min per 1.73 m2	31±11	28±11	0.94
Change in systolic BP,a mmHg	2±17	−5±18	0.25
Change in weight,a kg	−1.8±3.8	−1.1±6.0	0.65
Received sodium polystyrene sulfonate, n/N (%)	2/21 (9.5)	10/21 (47.6)	0.02
Time on sodium polystyrene sulfonate,b mo	1.5±0.7	19.5±5.4
Sodium polystyrene sulfonate dose,b g/d	11.3±5.3	19.8±7.8
Potassium data
Mean serum potassium,c mEq/L	4.8±0.4	4.6±0.5	0.03
Change in serum potassium,a mEq/L	0.1±0.7	−0.1±0.8	0.40
Serum potassiumd <4.5 mEq/L n/N (%)	14/76 (21)	32/65 (42)	0.002
Change in 24-h urinary potassium,a mEq/24 h	2.3 (−46–65)	−7.9 (−40–29)	0.24
Dietary nutrient data
Mean dietary potassium,c,e mg/d	3874 (2769–4812)	3272 (2524–3954)	0.001
Change in dietary potassium,a,e mg/d	−343 (−999–153)	−854 (−1606–0)	0.35
Change in dietary sodium,a mg/d	−115.6±1444.6	−768.3±1426.5	0.15
Change in protein,a mg/d	−17.3±41.0	−11.4±30.6	0.60
Change in energy,a kJ/d	1230±3859	1506±3442	0.81

Continuous variables are summarized as mean±SD.

^aChange refers to analysis of the change from baseline to final value.

^bAverage months and dose of sodium polystyrene sulfonate among participants who received the drug (n=2 control; n=10 intervention).

^cGroup mean data were assessed at 6-month intervals and are expressed as raw unadjusted means, with P values from generalized linear model analyses adjusted for baseline value.

^dProportions are over postrandomization visits assessed at 6-month intervals. P values are from a generalized linear model adjusting for baseline and account for the correlation within a patient over time.

^eIndicates variables that are not normally distributed and are summarized as median (interquartile range).